ethyl 4-hydroxy-6,7-bis(2-methoxyethoxy)quinoline-3-carboxylate | 1219717-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 4-hydroxy-6,7-bis(2-methoxyethoxy)quinoline-3-carboxylate
• CAS: 1219717-68-6
• 化学式: C₁₈H₂₃NO₇
• 分子量: 365.4
• InChiKey: YXXPUMUPHFUBLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  92.3
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 4-hydroxy-6,7-bis(2-methoxyethoxy)quinoline-3-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 6,7-bis(2-methoxyethoxy)quinolin-4-ol
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor

  摘要：

  The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.

  DOI：

  10.1021/jm901877j
• 作为产物：
  描述：

  1,3-diethyl 2-({[3,4-bis(2-methoxyethoxy)phenyl]amino}methylidene)propanedioate 以 二苯醚 为溶剂， 反应 2.0h， 生成 ethyl 4-hydroxy-6,7-bis(2-methoxyethoxy)quinoline-3-carboxylate
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor

  摘要：

  The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.

  DOI：

  10.1021/jm901877j

文献信息

• 一类多取代喹诺酮类化合物及其制备方法和用途
  申请人：中国科学院上海药物研究所

  公开号：CN107151240A

  公开（公告）日：2017-09-12

  本发明提供了一类多取代喹诺酮类化合物及其制备方法和用途，具体地，本发明提供了一种如下式Ⅰ所示的多取代喹诺酮化合物，其光学异构体，及药学上可接受的盐或溶剂合物，其中各基团的定义如说明书中所述。本发明的喹诺酮化合物具有优良的c-Met抑制活性，可以用于c-Met活性或表达量相关疾病的治疗。